De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors

被引：64

作者：

Peyre, Matthieu ^{[1
,2
,3
]}

Gauchotte, Guillaume ^{[4
]}

Giry, Marine ^{[3
]}

Froehlich, Sebastien ^{[5
]}

Pallud, Johan ^{[6
,7
,8
]}

Graillon, Thomas ^{[9
]}

Bielle, Franck ^{[10
]}

Cazals-Hatem, Dominique ^{[11
]}

Varlet, Pascale ^{[7
,8
,12
]}

Figarella-Branger, Dominique ^{[13
]}

Loiseau, Hugues ^{[14
]}

Kalamarides, Michel ^{[1
,2
,3
]}

机构：

[1] Grp Hosp Pitie Salpetriere, AP HP, Dept Neurosurg, Paris, France

[2] Univ Paris VI Pierre & Marie Curie, Paris, France

[3] Inst Cerveau & Moelle Epiniere, INSERM, Unit 1127, Paris, France

[4] CHRU, U954, INSERM, Dept Pathol, Nancy, France

[5] Hop Lariboisiere, AP HP, Dept Neurosurg, Paris, France

[6] Hop St Anne, Dept Neurosurg, Paris, France

[7] Paris Descartes Univ, Sorbonne Paris Cite, Paris, France

[8] Ctr Psychiat Neurosci, U894, INSERM, IMA BRAIN, Paris, France

[9] Hop La Timone, Dept Neurosurg, Marseille, France

[10] Hop La Pitie Salpetriere, AP HP, Dept Neuropathol, Paris, France

[11] Hop Beaujon, Dept Neuropathol, Clichy, France

[12] Hop St Anne, Dept Neuropathol, Paris, France

[13] Aix Marseille Univ, La Timone Hosp, AP HM, Dept Pathol & Neuropathol,CRO2, Marseille, France

[14] Hop Pellegrin, Dept Neurosurg, Bordeaux, France

来源：

NEURO-ONCOLOGY | 2018年 / 20卷 / 08期

关键词：

anaplastic; grade; 3; meningioma; prognosis; TERT; TERT PROMOTER MUTATIONS; CENTRAL-NERVOUS-SYSTEM; MALIGNANT MENINGIOMAS; SURVIVAL; CLASSIFICATION; METHYLATION; SURGERY; TUMORS; EXPERIENCE; RESECTION;

D O I：

10.1093/neuonc/nox231

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. Following recent studies underlining the differences between de novo and secondary anaplastic meningiomas and the prognostic value of telomerase reverse transcriptase (TERT) promoter mutation, we decided to conduct a multicenter retrospective study to address these questions and determine specific prognostic factors in each of these 2 anaplastic meningioma subgroups. Methods. Among the 68 meningioma cases initially selected, only 57 were confirmed as anaplastic meningiomas after centralized pathological review. TERT promoter mutation analysis was performed in all cases. Results. Median overall survival was 2.6 years and 5-year survival rate was 10%. This study confirmed the better prognosis of de novo anaplastic meningiomas (28 tumors) compared with secondary anaplastic meningiomas (29 tumors) (P = 0.02). In the "de novo" group, meningiomas diagnosed on histological anaplasia alone had a better prognosis than those in patients with a high number of mitoses with or without anaplasia (P = 0.01). In the "secondary" group, tumors demonstrate very heterogeneous clinical courses leading to malignant transformation, and time to first relapse as a low-grade tumor was a strong predictor of overall survival (P = 0.0007). TERT promoter mutation in anaplastic meningiomas was rare (14%) and did not influence overall survival but was associated with a shorter recurrence-free survival in the secondary anaplastic meningioma subgroup (P = 0.02). The absence of TERT promoter methylation, although rare (3/33 cases), may be associated with prolonged overall survival (P = 0.02). Conclusion. This study highlights the different prognoses of de novo and secondary anaplastic meningiomas with specific prognostic factors in each subgroup. The analysis of TERT mutation and methylation could provide additional prognostic insights.

引用

页码：1113 / 1121

页数：9

共 29 条

[1] ARID1A and TERT promoter mutations in dedifferentiated meningioma [J].